Fig. 1.

SH2 domain tyrosine phosphorylation was detected in AML, CLL, multiple myeloma cells. A Relative MS signal intensities of SFK SH2 domain tyrosine phosphorylation in 12 primary AML samples and B five Revlimid-treated CLL patient samples. C Bar graphs of phosphorylation stoichiometry of Lyn Y¹⁹⁴ determined in human multiple myeloma tumor-derived cell lines. The cells were either untreated or treated with pervanadate prior to lysis. D Structure-based sequence alignment of SFK SH2 domains, with residue numbering based on mouse Lyn. The secondary structure elements of Lyn are indicated. Tyrosine 194 is indicated by a red box. Residues involved in the pY or pY+3 pockets are marked with an orange or green box, respectively.